AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27981366 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sample during all cycles
Number of subjects: 0
Study 25670361 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g of almonds daily for 4 weeks
Number of subjects: 48
Study 25670361 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic Lifestyle Changes Diet counseling (control)
Number of subjects: 48
Study 23302220 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine (2g granules taken up to twice a day for 12 weeks)
Number of subjects: 108
Study 23302220 — intervention group
Group type: COMPARATOR
Intervention: Placebo granule formulation
Number of subjects: 108
Study 21530092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy/Motivational Enhancement Therapy (CBT/MET)
Number of subjects: 0
Study 21530092 — intervention group
Group type: COMPARATOR
Intervention: Naturalistic treatment (Control)
Number of subjects: 0
Study 19233049 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and other disease-modifying anti-rheumatic drugs (DMARDs)
Number of subjects: 0
Study 19233049 — intervention group
Group type: EXPERIMENTAL
Intervention: Early therapy
Number of subjects: 0
Study 19233049 — intervention group
Group type: COMPARATOR
Intervention: Delayed therapy
Number of subjects: 0
Study 16676337 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment rate
Number of subjects: 429
Study 16676337 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention rate
Number of subjects: 429
Study 12638400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 75 mg qid for 3 days
Number of subjects: 0
Study 12638400 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 1000 mg qid for 3 days
Number of subjects: 0
Study 10832216 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms plasma-derived hepatitis B vaccine
Number of subjects: 50
Study 10832216 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms plasma-derived hepatitis B vaccine
Number of subjects: 50
Study 9174299 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 20
Study 9174299 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 20
Study 9174299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 20
Study 8018138 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR
Number of subjects: 62
Study 8018138 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 62
Study 3942473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 70
Study 3942473 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 70
Study 3942473 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus active placebo
Number of subjects: 70
Study 3942473 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus pharmacotherapy
Number of subjects: 70
Study 3942473 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment response
Number of subjects: 70
Study 3942473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysfunctional attitudes measure
Number of subjects: 70
Study 3942473 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual depression levels
Number of subjects: 70
Study 30538078 — intervention group
Group type: EXPERIMENTAL
Intervention: Offensive task
Number of subjects: 12
Study 30538078 — intervention group
Group type: EXPERIMENTAL
Intervention: Defensive task
Number of subjects: 12
Study 30538078 — intervention group
Group type: EXPERIMENTAL
Intervention: Short regime
Number of subjects: 12
Study 30538078 — intervention group
Group type: EXPERIMENTAL
Intervention: Long regime
Number of subjects: 12
Study 30538078 — intervention group
Group type: EXPERIMENTAL
Intervention: Offense-long SSG
Number of subjects: 12
Study 30538078 — intervention group
Group type: EXPERIMENTAL
Intervention: Defense-short SSG
Number of subjects: 12
Study 30538078 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-SSGs
Number of subjects: 12
Study 30538078 — intervention group
Group type: EXPERIMENTAL
Intervention: Offense-short SSG
Number of subjects: 12
Study 30538078 — intervention group
Group type: EXPERIMENTAL
Intervention: Defense-long SSG
Number of subjects: 12
Study 29132477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal nerve preservation (Group A)
Number of subjects: 84
Study 29132477 — intervention group
Group type: COMPARATOR
Intervention: Wide elective division of ilioinguinal nerve (Group B)
Number of subjects: 84
Study 26071306 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic feedback and referral to online and telephone services for health risk behaviours.
Number of subjects: 100
Study 26071306 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 100
Study 23462477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (school-based intervention)
Number of subjects: 226
Study 23462477 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 226
Study 21401682 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop
Number of subjects: 223
Study 21401682 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture
Number of subjects: 223
Study 21401682 — intervention group
Group type: COMPARATOR
Intervention: Self-Directed Learning (SDL)
Number of subjects: 223
Study 19682321 — intervention group
Group type: COMPARATOR
Intervention: Ziconotide monotherapy
Number of subjects: 28
Study 19682321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziconotide (in combination with other IT agents)
Number of subjects: 28
Study 19682321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17148528 — intervention group
Group type: EXPERIMENTAL
Intervention: Case conferences
Number of subjects: 461
Study 17148528 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner education
Number of subjects: 461
Study 17148528 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 461
Study 12753571 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 15
Study 12753571 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg)
Number of subjects: 15
Study 12753571 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam (15 mg)
Number of subjects: 15
Study 12753571 — intervention group
Group type: COMPARATOR
Intervention: Control (Triazolam)
Number of subjects: 15
Study 11641942 — intervention group
Group type: EXPERIMENTAL
Intervention: Epifamine (400 mg course dose)
Number of subjects: 9
Study 11641942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9232978 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk group
Number of subjects: 350
Study 9232978 — intervention group
Group type: EXPERIMENTAL
Intervention: Run group
Number of subjects: 350
Study 8425683 — intervention group
Group type: EXPERIMENTAL
Intervention: Actively smoking
Number of subjects: 30
Study 8425683 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 30
Study 3595078 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (0.1 microgram min‐1 kg‐1)
Number of subjects: 6
Study 3595078 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (1 microgram min‐1 kg‐1)
Number of subjects: 6
Study 3595078 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study 29258938 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroendoscopy
Number of subjects: 213
Study 29258938 — intervention group
Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 213
Study 26439114 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lifestyle advice program + pelvic floor muscle training (PFMT)
Number of subjects: 109
Study 26439114 — intervention group
Group type: COMPARATOR
Intervention: Structured lifestyle advice program
Number of subjects: 109
Study 25915721 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft splinting
Number of subjects: 17
Study 25915721 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual stretching
Number of subjects: 17
Study 25915721 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 17
Study 23731594 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems-level intervention consisting of a menu of evidence-based implementation strategies for increasing colorectal cancer screening.
Number of subjects: 16
Study 23731594 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation outcomes informed by the RE-AIM conceptual framework.
Number of subjects: 16
Study 22133240 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation cycling (FESC)
Number of subjects: 30
Study 22133240 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive cycling (PC)
Number of subjects: 30
Study 22133240 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncycling, electrically stimulated exercise (ES)
Number of subjects: 30
Study 19745643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (360 mg)
Number of subjects: 16
Study 19745643 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 16
Study 19745643 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 16
Study 19745643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17009343 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to Stress Questionnaire‐cancer version (RSQ‐CV)
Number of subjects: 232
Study 15328675 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray, 2 sprays per nostril twice daily
Number of subjects: 334
Study 15328675 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray, 2 sprays per nostril twice daily plus fexofenadine, 60 mg twice daily
Number of subjects: 334
Study 15328675 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) nasal spray and placebo capsules twice daily
Number of subjects: 334
Study 11177420 — intervention group
Group type: EXPERIMENTAL
Intervention: Restitution training (PeriMa program)
Number of subjects: 32
Study 11177420 — intervention group
Group type: EXPERIMENTAL
Intervention: Restitution training (PeriForm)
Number of subjects: 32
Study 11177420 — intervention group
Group type: EXPERIMENTAL
Intervention: Restitution training (PeriColor)
Number of subjects: 32
Study 11177420 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional perimetry (experimental group)
Number of subjects: 32
Study 11177420 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (fixation training, PeriMa)
Number of subjects: 32
Study 11177420 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (fixation training, PeriForm)
Number of subjects: 32
Study 11177420 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (fixation training, PeriColor)
Number of subjects: 32
Study 11177420 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between PeriMa and PeriForm
Number of subjects: 32
Study 11177420 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between PeriMa and PeriColor
Number of subjects: 32
Study 9301445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 100 mg/m2 combined with 5-fluorouracil (5-FU) 1000 mg/m2 continuous infusion from days 1-5 (Arm A)
Number of subjects: 88
Study 9301445 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CDDP) alone (Arm B)
Number of subjects: 88
Study 7687708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 114
Study 2442513 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 25
Study 2442513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 29505101 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg JNJ-54861911 once daily for 7 days
Number of subjects: 64
Study 29505101 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg JNJ-54861911 once daily for 7 days
Number of subjects: 64
Study 29505101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 29505101 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin
Number of subjects: 64
Study 29505101 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg JNJ-54861911 once daily for 7 days
Number of subjects: 64
Study 29505101 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg JNJ-54861911
Number of subjects: 64
Study 27807925 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 75 mg/day
Number of subjects: 30
Study 27807925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25010303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg plus sildenafil 50 mg
Number of subjects: 101
Study 25010303 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg plus placebo
Number of subjects: 101
Study 23516873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 20
Study 23516873 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 20
Study 20822543 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component physical activity intervention delivered by childcare service staff
Number of subjects: 300
Study 20822543 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 300
Study 18367288 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy (TRT) with a planned dose of 50Gy in 2Gy daily fractions, initiated with the fourth chemotherapy cycle.
Number of subjects: 267
Study 18367288 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard chemo-radiotherapy without specified intervention details.
Number of subjects: 267
Study 22036029 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg body weight
Number of subjects: 48
Study 22036029 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg body weight
Number of subjects: 48
Study 22036029 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg body weight
Number of subjects: 48
Study 22036029 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg advantame/day (split into 3 doses per day)
Number of subjects: 48
Study 22036029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16088265 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body therapy (structured 60-hour training program over 10 weeks including stress management training, moderate exercise, Mediterranean diet, behavioral techniques and self-care strategies)
Number of subjects: 30
Study 16088265 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body therapy
Number of subjects: 30
Study 16088265 — intervention group
Group type: COMPARATOR
Intervention: Usual-care waiting control group
Number of subjects: 30
Study 12017349 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin 3 to 20 mg/m2 of body surface area infused over 1.5 to 45 minutes
Number of subjects: 69
Study 12017349 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin
Number of subjects: 69
Study 10874370 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days oral chloroquine plus single dose sulphadoxin/pyrimethamine (CQ + SP)
Number of subjects: 784
Study 10874370 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days oral quinine plus single dose sulphadoxin/pyrimethamine (Q3 + SP)
Number of subjects: 784
Study 8573234 — intervention group
Group type: EXPERIMENTAL
Intervention: Rooming-in (extended and early contact)
Number of subjects: 31
Study 8573234 — intervention group
Group type: COMPARATOR
Intervention: Minimal contact (contact only during feedings)
Number of subjects: 31
Study 2676668 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test
Number of subjects: 99
Study 2676668 — intervention group
Group type: COMPARATOR
Intervention: Meal tolerance test
Number of subjects: 99
Study 134722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropiumbromide by inhalation (max dose 2.4 mg)
Number of subjects: 43
Study 134722 — intervention group
Group type: COMPARATOR
Intervention: Atropine sulphate by inhalation (1.6 mg and 2.4 mg)
Number of subjects: 43
Study 134722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropiumbromide by i.v. injection (max dose 0.28 mg)
Number of subjects: 43
Study 134722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropiumbromide by i.v. injection (0.28 mg)
Number of subjects: 43
Study 134722 — intervention group
Group type: COMPARATOR
Intervention: Atropine sulphate by inhalation
Number of subjects: 43
Study 134722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropiumbromide by inhalation
Number of subjects: 43
Study 11454180 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN 4.5 MU daily plus amantadine 200 mg/day for 4 weeks and then IFN 6 MU thrice weekly plus amantadine 200 mg/day for an additional 5 months (group A)
Number of subjects: 40
Study 11454180 — intervention group
Group type: COMPARATOR
Intervention: IFN alone at the same dosage and duration (group B)
Number of subjects: 40
Study 30768419 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicago Parent Program (CPP)
Number of subjects: 158
Study 30768419 — intervention group
Group type: COMPARATOR
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 158
Study 29452812 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body warming
Number of subjects: 123
Study 26964861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative retractor sponge
Number of subjects: 188
Study 26964861 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Trendelenburg position)
Number of subjects: 188
Study 24617731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion with bone marrow‐derived mononuclear cells (BMMCs)
Number of subjects: 152
Study 24617731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion with peripheral blood‐derived mononuclear cells (PBMCs)
Number of subjects: 152
Study 24617731 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 152
Study 22137804 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal blood glucose strategy (121‐180 mg/dL)
Number of subjects: 189
Study 22137804 — intervention group
Group type: COMPARATOR
Intervention: Strict blood glucose strategy (90‐120 mg/dL)
Number of subjects: 189
Study 20373139 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 120
Study 20373139 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 120
Study 17365165 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirituality intervention in persons living with HIV disease
Number of subjects: 0
Study 17365165 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirituality intervention in healthy adults
Number of subjects: 0
Study 15972045 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (Botox)
Number of subjects: 38
Study 15972045 — intervention group
Group type: COMPARATOR
Intervention: Sphincterotomy
Number of subjects: 38
Study 12628944 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (300 mg daily for 6 weeks)
Number of subjects: 872
Study 12628944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 872
Study 12628944 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 872
Study 11783213 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine mixture (CHMM)
Number of subjects: 0
Study 9117472 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated service agency program
Number of subjects: 0
Study 9117472 — intervention group
Group type: COMPARATOR
Intervention: Usual services (comparison group)
Number of subjects: 0
Study 1751351 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% plain lignocaine
Number of subjects: 32
Study 1751351 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine with adrenaline 1:200,000
Number of subjects: 32
Study 1751351 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium metabisulphite in adrenalized lignocaine
Number of subjects: 32
Study 1751351 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralization of acidic 0.5% lignocaine (pH 4.7)
Number of subjects: 32
Study 1751351 — intervention group
Group type: COMPARATOR
Intervention: 0.5% plain lignocaine
Number of subjects: 32
Study 6753706 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole-naproxen
Number of subjects: 65
Study 6753706 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 65
Study 30101576 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved nutrition with infant and young child feeding messages and lipid-based nutrient supplementation (N)
Number of subjects: 4718
Study 30101576 — intervention group
Group type: EXPERIMENTAL
Intervention: N+WSH (Nutrition + Water, Sanitation, and Handwashing)
Number of subjects: 4718
Study 30101576 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 4718
Study 30101576 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplementation
Number of subjects: 4718
Study 29330071 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (300 U into ankle plantar flexors; ≤100 U optional lower limb muscles)
Number of subjects: 468
Study 29330071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 29330071 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA/onabotulinumtoxinA
Number of subjects: 468
Study 29330071 — intervention group
Group type: COMPARATOR
Intervention: Placebo/onabotulinumtoxinA
Number of subjects: 468
Study 29330071 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 468
Study 24802769 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive compression therapy (ACT) system
Number of subjects: 90
Study 24802769 — intervention group
Group type: COMPARATOR
Intervention: Conventional four-layer bandage system
Number of subjects: 90
Study 25191981 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP infusion (100 μg/kg/min)
Number of subjects: 10
Study 25191981 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 10
Study 22230722 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF
Number of subjects: 8
Study 22230722 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride
Number of subjects: 8